Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue growth accelerates
Q2 FY2026 cost of revenue of $10.94M rose 46.0% year over year, ahead of the +43.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at +265.1% a year.
Context
- Cost of revenue amounted to 9.8% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +46.0% holds above the trailing-twelve-month pace of +43.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 36.7M USD
- Year-over-year change
- +91.8%
- 4-year CAGR
- +163.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.7M | +91.8% |
| FY2024 | 2024-12-31 | 19.13M | +283.6% |
| FY2023 | 2023-12-31 | 4.99M | +561.4% |
| FY2022 | 2022-12-31 | 754K | -1.2% |
| FY2021 | 2021-12-31 | 763K | — |
Cost of Revenue vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's LTM Jun 2026 cost of revenue of $41.1M is the highest of the 6 companies compared; the peer median is $66.6K.
- Its year-over-year change of +43.0% is the highest of 3, against a peer median of -93.0%.
- Cost of revenue amounts to 8.9% of revenue for ARQT, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $41.1M | +43.0% | +265.1% | 8.9% | |
| LTM Mar 2026 | $1.98M | -86.0% | -44.1% | 23.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $724K | — | — | 7.2% |
| LTM Mar 2026 | $66.6K | — | — | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $42.29K | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | -79.5% | 0.0% | |
| Peer median (excluding ARQT) | $66.6K | -93.0% | -61.8% | 7.2% | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | 763K | 754K | 4.99M | 19.13M | 36.7M |
| Gross Profit | (763K) | 2.93M | 54.62M | 177.41M | 339.38M |
| Gross Margin | — | 79.5% | 91.6% | 90.3% | 90.2% |
| Research & Development | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
| Selling, General & Admin | 60.97M | 122.12M | 185.15M | 229.39M | 274.55M |
| Operating Expenses | 205.77M | 304.56M | 295.72M | 305.81M | 351.6M |
| Depreciation & Amortization | 454K | 934K | 750K | 2.6M | 4.67M |
| EBITDA | (205.9M) | (294.87M) | (228.57M) | (109.63M) | 1.78M |
| EBITDA Margin | — | -7999.8% | -383.5% | -55.8% | 0.5% |
| Operating Income | (206.53M) | (301.63M) | (241.1M) | (128.4M) | (12.23M) |
| Operating Margin | — | -8183.0% | -404.5% | -65.3% | -3.3% |
| Interest Income | 173K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 15.65M | 29.71M | 27.17M | 12.08M |
| Other Income / Expenses | 173K | (9.83M) | (17.93M) | (11M) | (2.74M) |
| Income Before Tax | (206.36M) | (311.46M) | (259.03M) | (139.39M) | (14.97M) |
| Pre-Tax Margin | — | -8449.8% | -434.6% | -70.9% | -4.0% |
| Income Tax Expense | 0 | 0 | 3.11M | 647K | 1.17M |
| Net Income | (206.36M) | (311.46M) | (262.14M) | (140.04M) | (16.14M) |
| Net Margin | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| EPS (Basic) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| EPS (Diluted) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| Weighted Avg Shares | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
| Weighted Avg Shares (Diluted) | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.